Down-regulation of miR-24 in diabetes: a novel insight into the mechanism of diabetic exacerbation of myocardial ischaemia-reperfusion injury
Editorial Commentary

Down-regulation of miR-24 in diabetes: a novel insight into the mechanism of diabetic exacerbation of myocardial ischaemia-reperfusion injury

Robert M. Bell, Derek M. Yellon

Hatter Cardiovascular Institute, University College London, London, UK

Correspondence to: Professor Derek Yellon. Director of the Hatter Cardiovascular Institute, UCL, London, UK. Email:

Comment on: Wang D, Hu X, Lee SH, et al. Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation. JACC Basic Transl Sci 2018;3:350-62.

Received: 10 August 2018; Accepted: 19 December 2019; Published: 31 March 2020.

doi: 10.21037/ncri.2020.01.01

Diabetes is an important cardiovascular risk factor, contributing to the development of arterial atherosclerosis. Consequently, approximately 20% of all patients experiencing an acute coronary syndrome also suffer from this debilitating disorder of glucose homeostasis (1). Unfortunately, diabetes represents much more than a simple cardiovascular risk factor: diabetic patients not only experience more recurrent acute coronary syndromes than non-diabetics, but also suffer larger myocardial infarcts and greater morbidity and mortality, even following expedient and successful percutaneous intervention.

Current clinical management of diabetes to date remains focused upon the most easily measured derangement of normal physiology: hyperglycaemia. Pharmacological interventions have therefore concentrated upon augmenting insulin release, supplementing insulin exogenously or augmenting tissue sensitivity to insulin in an attempt to overcome the evolved insulin resistance characterised by type 2 diabetes mellitus. While this approach is effective in attenuating the microvascular complications of diabetes, until very recently, management of hyperglycaemia alone has proven disappointing in avoiding the macrovascular complications with negligible impact upon cardiovascular outcomes. Moreover, while mortality and morbidity from coronary artery disease has been in decline for the last five decades, this hard-won battle is currently under threat from the worldwide diabetic pandemic. Given the inflationary pressures upon mortality and morbidity posed by diabetes, understanding the mechanisms underlying the interaction between diabetes and cardiovascular disease is essential. Recent favourable data from the clinical outcome trials of sodium-glucose co-transporter (SGLT) inhibition (2,3) and glucagon-like peptide-1 (GLP-1) receptor agonists (4) is a pleasing, if a somewhat unexpected finding; the mechanisms underlying their cardiovascular mortality benefits remain unclear, although a number of mechanisms have been speculated (5). Notwithstanding, identifying the deleterious mechanisms and attempting to break the dangerous circle of diabetes, coronary artery disease and acute myocardial ischaemia resulting from coronary syndromes, and thus identifying potential targets for therapeutic intervention in diabetes beyond pure sugar control, remain an urgent clinical need.

Micro-ribonucleic acids (miRNAs), small 21-23 nucleotide non-coding RNAs, are well recognised in their role in both physiological and pathophysiological processes to control cellular differentiation, proliferation and survival. In the context of myocardial ischaemia-reperfusion injury (6), miRNAs have been widely been shown to impact on pro-cell death pathways (necrosis, apoptosis, pyroptosis, necroptosis) and canonical cardioprotective pathways, including the reperfusion injury salvage (RISK) pathways (PI3K/Akt, MEK/ERK) and survivor activating factor enhancement (SAFE) pathway (Jak/STAT), in either a positive or deleterious fashion, as reviewed (7,8). Similarly, diabetes also impacts miRNA expression in the heart, implicated for example, in the evolution of diabetic cardiomyopathies (9) and cardiovascular disease (10). Interestingly, the detrimental diabetic phenotype is characterised by deleterious regulation of miRNAs that have the potential to augment myocardial ischaemia-reperfusion injury and down-regulate endogenous cardioprotective mechanisms. In a recent issue of the Journal of the American College of Cardiology, Wang et al. (11) report of one such diabetes-miRNA interaction that falls into the latter camp. Their principle finding is down-regulation of miR-24 in diabetes, with a consequent exacerbation of myocardial infarct size in in-vivo murine heart following injurious ischaemia-reperfusion injury.

miR-24 is part of a primary miRNA cluster comprising of miR-23 and miR-27 on chromosome 9 (9q22.32, miR-24.1) and 19 (19p13.13, miR-24.2), that is highly conserved across mammalian species (12,13). Interestingly, miR-24 has previously been shown to be important in the evolution of adverse remodelling to pressure overload and myocardial injury following ischaemia-reperfusion injury [including after remote ischaemic conditioning (14)], although not always in a beneficial way (15-17). While miR-24 may exacerbate myocardial fibrosis, it also attenuates apoptosis (18-20), and the latter attenuation of cell death may be particularly useful in the context of acute myocardial ischaemia-reperfusion injury. miR-24 expression is also significantly regulated by diabetes, and while there is some controversy in this area, circulating and tissue miR-24 appears suppressed in patients with, and in animal models of type 2 diabetes (21-24) [reviewed (12)].

Wang et al. (11) demonstrate, as expected, that myocardial ischaemia-reperfusion injury is exacerbated by diabetes. Interestingly, the largest infarcts were found in the type2 diabetic db/db mice compared to the streptozotocin type1 diabetic animals or controls. Somewhat intriguingly, 28-day post infarct survival was worst in type 2 diabetic animals concomitantly treated with insulin but conversely, insulin therapy had a survival benefit in type 1 diabetic animals. These data suggest that insulin therapy to replace insufficient insulin production is likely beneficial, but detrimental when used under circumstances of high insulin resistance.

Disappointingly, in this study, the authors have not measured the circulating or tissue levels of miR-24 in these diabetic animals to correlate to final infarct size and survival, but they did examine circulating miR-24 in human subjects. In diabetic patients, miR-24 levels were lower in type2 diabetics compared to type 1, and lower still in type 2 subjects treated with insulin. The logical hypothesis from these data is that insulin therapy in type 2 diabetics has the potential to exacerbate myocardial injury through augmented depletion of miR-24. Certainly, despite the encouraging data from the DIAGAMI-1 study (25), subsequent insulin-based interventions designed to manage hyperglycaemia in patients presenting with an acute coronary syndrome, have proven disappointing. Whether the benefits of controlling hyperglycaemia by intensive insulin therapy following myocardial ischaemia-reperfusion are entirely countered by pro-injurious depletion of miR-24 in patients with established type 2 diabetes is unclear, but it does represent an intriguing hypothesis that can be tested.

To demonstrate causality between miR-24 and myocardial resistance to injurious ischaemia-reperfusion injury, the authors adopted two approaches: pharmacological and genetic. Administering exogenous miR-24 to type2 diabetic db/db mice 2-week prior to subjecting the animals to coronary occlusion not only restored tissue miR-24 levels, but also abrogated the excess myocardial injury associated with the type 2 diabetic phenotype. Remarkably, the exogenous miR-24 also led to a fall of circulating glucose and insulin levels, suggesting that miR-24 may have a role in regulating tissue insulin sensitivity.

The genetic manipulation approach applied is interesting: a cardiomyocyte-specific up-regulation of miR-24, thus avoiding whole-body effects of increased tissue expression. Compared to wild-type littermates, over-expression of miR-24 led to a 40% reduction of infarct size. miR-24 has already been associated with the regulation of a large number of important cell-death pathways, including BIM and Bcl-2 (13), but Wang et al. (11) also identify additional, novel targets relevant to their diabetic models, including the autophagic pathway regulator, ATG-4a and the O-GlcNAc transfer protein, OTG. Transfection of isolated primary mouse cardiomyocytes with the miR-24-mimic (Ambion mirVana) significantly suppressed expression of BIM, ATG-4a and OTG. Moreover, miR-24 also abrogated the upregulation of OGT by insulin in high-glucose cell culture and, in the miR-24 over-expressing mice, attenuated OGT expression and O-GlcNAcylation in heart lysates.

Thus, Wang et al. reveal a novel paradigm of miR-24 suppression in diabetic subjects with concomitant increases in O-GlcNAcylation and dysregulation of pro-death pathways. That these deleterious pathways may potentially be further augmented by insulin therapy in type2 diabetic patients strikes a potentially cautionary note in the management of these patients that deserves further scrutiny. However, it would seem that miR-24 is a potential pharmacological target for future drug development, and it would be fascinating to see whether the recent remarkable improvements in cardiovascular outcomes resulting from the outcome trials in SGLT2 inhibitors and the GLP-1 receptor agonists are also associated with alterations in miR-24 expression.


Funding: None.


Provenance and Peer Review: This article was commissioned and reviewed by the Section Editor Dr. Shengguang Ding (Section Editor, The Second Affiliated Hospital of Nantong University, Nantong, China).

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See:


  1. Bebb O, Hall M, Fox KAA, et al. Performance of hospitals according to the ESC ACCA quality indicators and 30-day mortality for acute myocardial infarction: national cohort study using the United Kingdom Myocardial Ischaemia National Audit Project (MINAP) register. Eur Heart J 2017;38:974-82. [Crossref] [PubMed]
  2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New Engl J Med 2015;373:2117-28. [Crossref] [PubMed]
  3. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-57. [Crossref] [PubMed]
  4. Buse JB. the LSC. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:1798-9. [PubMed]
  5. Bell RM, Yellon DM. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. Lancet Diabetes Endocrinol 2018;6:435-7. [Crossref] [PubMed]
  6. Bell RM, Botker HE, Carr RD, et al. 9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Basic Res Cardiol 2016;111:41. [Crossref] [PubMed]
  7. Ong SB, Katwadi K, Kwek XY, et al. Non-coding RNAs as therapeutic targets for preventing myocardial ischemia-reperfusion injury. Expert Opin Ther Targets 2018;22:247-61. [Crossref] [PubMed]
  8. Lucas T, Bonauer A, Dimmeler S. RNA Therapeutics in Cardiovascular Disease. Circ Res 2018;123:205-20. [Crossref] [PubMed]
  9. Palomer X, Pizarro-Delgado J, Vazquez-Carrera M. Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets? Trends Pharmacol Sci 2018;39:452-67. [Crossref] [PubMed]
  10. De Rosa S, Arcidiacono B, Chiefari E, et al. Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links. Front Endocrinol (Lausanne) 2018;9:2. [Crossref] [PubMed]
  11. Wang D, Hu X, Lee SH, et al. Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation. JACC Basic Transl Sci 2018;3:350-62. [Crossref] [PubMed]
  12. Xiang Y. miR-24 in diabetes. Oncotarget 2015;6:16816-7. [Crossref] [PubMed]
  13. Katoh M. Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front Cell Dev Biol 2014;2:61. [Crossref] [PubMed]
  14. Minghua W, Zhijian G, Chahua H, et al. Plasma exosomes induced by remote ischaemic preconditioning attenuate myocardial ischaemia/reperfusion injury by transferring miR-24. Cell Death Dis 2018;9:320. [Crossref] [PubMed]
  15. Li RC, Tao J, Guo YB, et al. In vivo suppression of microRNA-24 prevents the transition toward decompensated hypertrophy in aortic-constricted mice. Circ Res 2013;112:601-5. [Crossref] [PubMed]
  16. Wang J, Song Y, Zhang Y, et al. Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res 2012;22:516-27. [Crossref] [PubMed]
  17. Fiedler J, Jazbutyte V, Kirchmaier BC, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011;124:720-30. [Crossref] [PubMed]
  18. Pan LJ, Wang X, Ling Y, et al. MiR-24 alleviates cardiomyocyte apoptosis after myocardial infarction via targeting BIM. Eur Rev Med Pharmacol Sci 2017;21:3088-97. [PubMed]
  19. Qian L, Van Laake LW, Huang Y, et al. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med 2011;208:549-60. [Crossref] [PubMed]
  20. Guo C, Deng Y, Liu J, et al. Cardiomyocyte-specific role of miR-24 in promoting cell survival. J Cell Mol Med 2015;19:103-12. [Crossref] [PubMed]
  21. Deng X, Liu Y, Luo M, et al. Circulating miRNA-24 and its target YKL-40 as potential biomarkers in patients with coronary heart disease and type 2 diabetes mellitus. Oncotarget 2017;8:63038-46. [PubMed]
  22. Xiang Y, Cheng J, Wang D, et al. Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood 2015;125:3377-87. [Crossref] [PubMed]
  23. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010;107:810-7. [Crossref] [PubMed]
  24. Huang B, Qin W, Zhao B, et al. MicroRNA expression profiling in diabetic GK rat model. Acta Biochim Biophys Sin (Shanghai) 2009;41:472-7. [Crossref] [PubMed]
  25. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512-5. [Crossref] [PubMed]
doi: 10.21037/ncri.2020.01.01
Cite this article as: Bell RM, Yellon DM. Down-regulation of miR-24 in diabetes: a novel insight into the mechanism of diabetic exacerbation of myocardial ischaemia-reperfusion injury. Non-coding RNA Investig 2020;4:1.

Download Citation